Maxamine enhances IL-2 in phase 3 malignant cancer.
Zuboy
J
J
D008735:5-Methoxytryptamine / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
D007376:Interleukin-2; D008735:5-Methoxytryptamine